OSUCCC Administration, rated as """"""""Outstanding to Excellent"""""""" in 1999 and """"""""Outstanding"""""""" in 2004, is responsible for the accounting, finance, human resources, information systems, meeting planning, grants administration, document preparation, procurement, travel, marketing and facilities management required to support the operations of the OSUCCC. Since 2004, The OSUCCC Administration infrastructure has expanded from 30.6 FTEs to 59 FTEs in order to adequately support: 1) a 72% increase in NCI funding and a 35% increase in overall peer-reviewed, cancer-relevant grant funding;2) an increase in the number of shared resources, from 16 to 18 with 2 more in development;3) the recruitment of 159 new cancer faculty;4) increased inter- and intra-programmatic research activities including 41 funded and/or newly submitted POl, P50, U01, U10, SPORE and Tobacco Settlement grant applications;5) over a 274% increase in investigator-initiated clinical trial accrual;6) management of approximately 300,000 square feet of research and administration space and ongoing planning efforts for the construction of an additional 125,000 nsf of new research space by 2016;and, 7) expanded planning and evaluation activities. Overall, the responsibility of OSUCCC Administration continues to be to support and facilitate the conduct of leading-edge cancer research. The CCC administrative support offices were relocated in 2006 from space within the Martha Morehouse Medical Complex to the Ackerman facility located 0.3 miles from the OSUCCC research and medical facilities. The Ackerman facility provides 13,000 nsf (a 217% increase in space) of centralized and fully equipped office space to comfortably accommodate the large administrative team while also providing room for future growth. In addition to full tele- and videoconferencing capabilities, a continuous shuttle service provides convenient and efficient access for Administration to all OSUCCC members and staff. As detailed in the table at the end of this section, in year 1 of the 2010 CCSG renewal, we are requesting funding for 6.75 of the 59 FTEs comprising OSUCCC Administration. In dollars, the CCSG request would fund 14.8% of the total OSUCCC Administration costs with the remaining 85.2% being institutionally supported. Overall, in year 1, Administration represents 10.9% ofthe total CCSG budget request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601803
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$419,142
Indirect Cost
$144,295
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications